CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Choroidal neovascularisation secondary to Best's disease in a 13-year-old boy treated by intravitreal bevacizumab.

BACKGROUND: To describe the effect of intravitreal bevacizumab for the treatment of choroidal neovascularisation secondary to vitelliform dystrophy of the macula (Best's disease).

METHODS: A 13-year-old boy with confirmed Best's disease presented with visual acuity (VA) loss due to secondary choroidal neovascularisation (CNV). He was treated with a single injection of 1-mg bevacizumab.

RESULTS: Best corrected VA (Snellen) fully recovered from 20/40 preoperatively to 20/20 over a period of 6 months. Optical coherence tomography (OCT) and angiography demonstrated regression of the CNV and resolution of the macular edema.

CONCLUSIONS: A single intravitreal injection of bevacizumab may be effective to induce morphologic and functional improvement in a juvenile suffering from CNV secondary to Best's disease.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app